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75-year-old man presented with pleuritic chest pain and right shoulder pain. A palpable right anterior chest wall mass was noted on physical examination. His past medical history was signifi cant for testicular cancer treated with radiation therapy in 1974.
A computed tomography (CT) scan of the chest, performed without intravenous contrast due to renal insuffi ciency, revealed an 8-cm lobulated soft tissue mass arising from the right third anterior rib and involving the costal cartilage ( Figure 1 ). Scattered internal calcifi c deposits were present. It was uncertain if these represented chondroid matrix or destruction of calcifi ed costal cartilage. Th e mass extended into the chest wall with elevation of the pectoralis muscles. Medially, the mass abutted the right anterior mediastinum. No additional osseous lesions or enlarged mediastinal or hilar nodes were seen. A few nonspecifi c 1-to 2-mm noncalcifi ed pulmonary nodules were noted. CT of the abdomen and pelvis showed no evidence of metastatic disease.
Given the internal calcifi cations, the leading diff erential diagnostic consideration was chondrosarcoma; however, the classic "ring and arc" calcifi cations described in chondroid neoplasms were not defi nitively present on imaging. Metastasis was another consideration given the patient's history of testicular cancer; however, the location and appearance would be very atypical. Th e lesion appeared to arise from the chest wall and not the lung itself. Other considerations would include extramedullary plasmacytoma or lymphoma.
An ultrasound-guided needle biopsy of the lesion, prepared for rapid cytologic evaluation using hematoxylin and eosin, showed a myxoid chondroid matrix with chondrocytes present (Figure 2) . Th e subsequently prepared paraffi n block from the core biopsy showed a similar chondroid matrix with increasing cellularity at the periphery of the nodule (Figure 3 ). Th ough no distinctly atypical chondrocytes were seen, the cellularity was concerning for a possible low-grade chondrosarcoma, and the tumor was excised along with the second, third, and fourth ribs. Grossly, the tumor did not involve the lateral margins but was 12 mm from the inferior resection margin of the fourth rib and 3 mm from the periosteal soft tissue of the superior aspect of the second rib. Th e neoplasm clearly demonstrated cartilage synthesis, as well as areas of hemorrhage and necrosis (50% of total tumor volume) (Figure 4) . Microscopically, the tumor showed features suggesting increasing histologic grade, such as areas with distinct marked hypercellularity, increasing nuclear size/atypia, and multinucleated cells ( Figure 5 ). However, the proliferation index, as demonstrated by MiB-1, was low, with most areas demonstrating 1% and focal areas demonstrating 5%. Th e tumor expanded the medullary cavity and in areas extended beyond the cortex, forming subpleural nodules posteriorly and involving the chest wall tissue anteriorly. Th e anterior chest wall surgical resection margin was focally involved by tumor. Extension through the pleural surface was not seen. Focal vascular invasion was present, with tumor grossly and microscopically surrounding and invading one blood vessel specifi cally. Th e tumor was considered grade 2.
Given the positive margin, radiation therapy was recommended. Th e patient received 3060 cGy of the planned 5940 cGy of radiation but could not complete the full course due to locoregional side eff ects. No additional therapy was recommended. A CT scan performed approximately 2 months after radiation therapy showed expected radiation changes and minimal pleural fl uid without overt evidence of tumor recurrence. Th e patient is currently 4 months postradiation.
DISCUSSION
Chondrosarcomas are malignant tumors that produce chondroid matrix. Primary chondrosarcomas arise de novo. Secondary chondrosarcomas occur in preexisting benign cartilaginous neoplasms, such as a complication of a preexisting enchondroma or osteochondroma (1, 2) . Tumors that arise in the medullary cavity are considered central, or conventional intramedullary, chondrosarcomas, while those that occur near the surface of bone are referred to as peripheral, or juxtacortical. Primary chondrosarcoma is the third most common primary malignant tumor of bone, but the most common primary neoplasm involving the chest wall (3). Ten percent of chondrosarcomas are radiation-induced (3). A wide variety of primary neoplasms are associated with radiation-induced chondrosarcoma, as follows: Hodgkin's lymphoma, breast adenocarcinoma, squamous cell carcinoma of the larynx, thyroid carcinoma, non-small cell lung carcinoma, and retinoblastoma (4) (5) (6) (7) (8) (9) (10) . Th is particular case was felt to represent a primary chondrosarcoma.
Chondrosarcomas tend to be bulky tumors. Most are >4 cm in diameter, and some grow as large as 25 or 35 cm. Th e most extensive tumors occur in the fl at and irregular bones, including the pelvis, ribs, and scapula, where they can grow to a large size before producing symptoms (11) . Long bones are involved approximately 45% of the time, with the femur most frequently aff ected, making up 25% of all cases. In the femur, humerus, tibia, and fi bula, the proximal metaphysis is aff ected more commonly than the distal (11) .
Conventional intramedullary chondrosarcomas typically occur in the fourth or fi fth decades, with a male to female predominance of 1.5 to 2:1. However, chondrosarcomas involving the ribs and sternum tend to occur in a slightly younger patient population. Within the chest, anterior ribs are most commonly involved, at the costochondral junction (3) .
Pain is the most frequent presenting symptom, reported in 95% of patients. Th e pain is often insidious and progressive, with an average duration of 1 to 2 years prior to presentation. Th e pain is typically described as aching at rest and worse, sometimes severe, at night. A palpable soft tissue mass or fullness is present in 30% to 80% of patients at presentation. Pathologic fractures are the presenting symptom in 3% to 17% of patients (3). Two syndromes characterized by multiple enchondromas, Maff ucci syndrome and Ollier's disease, have been described. Ollier's disease is more common than Maff ucci syndrome and is characterized by multiple enchondromatosis, which may involve a single limb, one half of the body, or the entire skeleton (1, 12, 13) . Maff ucci syndrome is the constellation of multiple enchondromatosis and soft tissue hemangiomas, with greatest involvement of the hands and feet. In fact, radiographs of the hands and feet are often pathognomonic in Maff ucci syndrome, showing multiple soft tissue masses containing phleboliths in addition to the multiple enchondromas (14) . Both processes potentially undergo malignant transformation. Th e range of malignant transformation to chondrosarcoma in Ollier's disease varies widely in the reported literature, ranging from 5% to 50%. In Maff ucci syndrome, the incidence of malignant transformation to chondrosarcoma is approximately 15% to 20%. However, the soft tissue hemangiomas can undergo malignant transformation to vascular sarcomas in 3% to 5% of cases. Th ere is also an increased incidence of ovarian and pancreatic malignancies and gliomas in patients with Maff ucci syndrome (14) .
Imaging considerations
Th e classic radiographic appearance of chondrosarcoma is a lobulated, mixed lytic and sclerotic lesion. Th e sclerotic regions on radiographs correspond to chondroid matrix mineralization. In more advanced stages, the mass becomes lobulated with endosteal scalloping and eventual cortical disruption and extension to the adjacent soft tissues. Higher-grade chondrosarcomas contain relatively less extensive chondroid matrix. Well-organized calcifi c rings within cartilage usually signify a low-grade tumor. High-grade chondrosarcomas may contain more myxoid material and are frequently associated with large areas of noncalcifi ed tumor matrix. When calcifi cation occurs in high-grade chondrosarcomas, it tends to be amorphous, scattered, punctuate, or irregular (11) . Th e degree of endosteal scalloping is considered the best predictor in distinguishing chondrosarcoma from benign enchondroma on radiographs. Deep endosteal scalloping and soft tissue expansion, which are both considered aggressive features, are better evaluated with CT. Endosteal scalloping greater than two thirds the cortical thickness in long bones is strong evidence of chondrosarcoma (3).
CT is optimal for detection and characterization of chondroid matrix, which classically has well formed rings and arcs of mineralization. Both CT and magnetic resonance imaging (MRI) depict high internal water content. MRI is the ideal modality to evaluate the extent of bone marrow involvement and extraosseous extension.
Nuclear imaging also plays a role in the evaluation of chondroid neoplasms. Th e role of skeletal scintigraphy is largely to determine a monostotic or polyostotic process. Positron emission tomography (PET) can provide more insight into the tumor grade. 18-fl uoro-2-deoxy-D-glucose (F18 FDG) uptake has been shown to be proportional to tumor grade, with high standardized uptake values predictive of highergrade chondrosarcomas. PET cannot diff erentiate benign cartilaginous tumor from grade 1/low-grade chondrosarcoma; however, PET is highly sensitive in detecting high-grade chondrosarcoma metastasis. PET can be useful in optimizing the biopsy approach and targeting regions of highest measured metabolic activity.
Molecular genetic considerations
Th ere is interobserver variability in the histologic grading of chondrosarcomas, yet signifi cantly diff erent therapeutic approaches are used for grade 1 versus grade 2 lesions. Th erefore, defi nitive molecular markers distinguishing these histologic subtypes are needed. Presently, such markers have not been delineated. However, when considering central and peripheral chondrosarcomas, diff erent molecular genetic profi les have been demonstrated.
Central chondrosarcomas, the most common type, are associated with genetic aberrations involving chromosome 12q13-15 and 9p21. Th e locus for CDKN2A (p16), a tumor suppressor gene, is located at 9p21. Th is marker is considered important in progression of chondrosarcoma from low to high grade. Mutations in TP53 are also associated with tumor progression (15) .
Peripheral chondrosarcomas are associated with exostosin (EXT) genes, which cause multiple osteochondromas. In the setting of a hereditary syndrome, germline mutations of EXT1 and EXT2 are present, with accompanying loss of the wildtype allele in the cartilage cap of the osteochondroma. When a peripheral chondrosarcoma is solitary, however, a homozygous deletion with decreased EXT expression in the preceding osteochondroma and subsequent peripheral chondrosarcoma is seen (15) . Th e function of EXT is to synthesize heparan sulfate, which stimulates the formation of heparan sulfate proteoglycans, which plays a role in cell signaling. Inactivation of EXT leads to accumulation of heparan sulfate proteoglycans within the cell cytoplasm and Golgi apparatus, and decreased signaling of growth pathways occurs (15) . Overexpression of platelet-derived growth factor receptor-alpha and -beta has also been described (15, 16) .
Pathology
Permeation of bone, size, and periosteal invasion are specifi c fi ndings of chondrosarcoma. Cellularity, nuclear atypia (including multinucleated cells) and increased proliferation (>10%) are all indicators of increasing grade and aggressive behavior. Apart from the typical chondrosarcomas, there are some rare types of this tumor including dediff erentiated chondrosarcoma, mesenchymal chondrosarcoma, clear cell chondrosarcoma, and myxoid chondrosarcoma. Th ese rare forms are more aggressive and malignant (15) . Chondrosarcomas associated with clinical syndromes were previously discussed.
Treatment
Th e natural history and prognosis of chondrosarcoma is extremely variable. Overall 5-year survival rates for grade 1 chondrosarcomas are 90% to 94%, while those for grade 3 are 43% to 44%. For grade 1 chondrosarcomas with intact cortex and absence of soft tissue mass, consideration can be given to an intralesional procedure such as curettage with adjunctive ablation. However, if there are aggressive imaging features such as cortical breakthrough or soft tissue mass, or if the tumor is grade 2 or higher, wide surgical excision is required (3) .
A Scandinavian study evaluated 106 consecutive chondrosarcomas involving the rib and sternum. Th e pathologic specimens were reviewed and graded 1 to 4, and the surgical margins were defi ned as wide, marginal, or intralesional. After wide surgical excision, the 10-year survival rate was 92%, and the local recurrence rate was 4%. In contrast, the 10-year survival rate was 47% and the local recurrence rate 73% in patients treated with an intralesional approach. Prognostic factors for local recurrence included both surgical margins and histologic grade (17) .
Due to the slow growth rate of chondrosarcomas-as supported by a low proliferation index with the Mib-1/Ki-67 proliferation marker-chondrosarcomas are known to be relatively radioresistant. Doses exceeding 60 Gy are recommended for eff ective treatment, which is often not tolerable for adjacent structures (e.g., neurologic tissue) (1, 15) .
Other treatment approaches have included particle therapy with protons, which off ers the advantage of a minimal exit dose after energy deposits within the tissue, thus eff ectively sparing adjacent structures (2) . Additionally, proton radiotherapy has proven benefi cial in the setting of incompletely resected chondrosarcomas present at the skull base and axial skeleton, with reported local control rates of 85% to 100% (18) . Another documented approach is the use of radiotherapy with carbon ions, providing the physical advantages of proton therapy combined with higher radiobiologic activity. Local control rates with this approach are 96% and 90% at 3 and 4 years, respectively (2) .
Chondrosarcomas present several architectural and structural barriers for systemic chemotherapy. In addition to their low proliferation index, they have poor vascularity and an abundant extracellular matrix that makes tumor perfusion diffi cult. Further, it is hypothesized that the expression of the multidrugresistance 1 gene (P-glycoprotein), which confers resistance to doxorubicin, off ers another explanation to the relative ineff ectiveness of chemotherapeutic regimens (2) . Th ere is no suggestion of benefi t for low-grade chondrosarcomas with adjuvant chemotherapy, even in the metastatic setting. However, chemotherapy may have some role to play in the treatment of tumors of dediff erentiated and mesenchymal subtypes (especially with increased small blue cells). Th is latter type of chondrosarcoma is especially chemotherapy sensitive, and tumor responses to conventional treatments have been noted. Specifi cally, Huvos et al (19) reported a median survival of 37.9 months, with a 50% 3-year survival, 42% 5-year survival, and 28% 10-year survival in a study of 32 patients. Cisplatin and Adriamycin-based regimens seem to have the most effi cacy. Investigational classes of drugs including tyrosine kinase inhibitors, hormonal therapies, and angiogenesis inhibitors are also being studied (15) . Th us, no standardized proven approach exists for adjuvant chemotherapy in the setting of chondrosarcoma.
